Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16396464 | 0.86 | MAPT (0.38) | MAPTNPC1DGAT1 | |
| Potassium Ion SCHEMBL1857153 | 0.83 | NPC1 (0.36) | MAPTNPC1DGAT1 | |
| SCHEMBL16396093 | 0.82 | MAPT (0.36) | MAPTNPC1DGAT1 | |
| Lithium Ion SCHEMBL17764412 | 0.79 | NPC1 (0.35) | MAPTNPC1DGAT1 | |
| Potassium Ion SCHEMBL3543627 | 0.79 | NPC1 (0.34) | MAPTNPC1DGAT1 | |
| SCHEMBL15572246 | 0.77 | DGAT1 (0.40) | MAPTNPC1DGAT1 | |
| SCHEMBL31324233 | 0.75 | DGAT1 (0.35) | MAPTNPC1DGAT1 | |
| SCHEMBL31457411 | 0.75 | DGAT1 (0.38) | MAPTNPC1DGAT1 | |
| Lithium Ion SCHEMBL9980476 | 0.74 | DGAT1 (0.41) | NPC1DGAT1 | |
| SCHEMBL23124121 | 0.73 | DGAT1 (0.38) | MAPTNPC1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | MAPT 3865/4885NPC1 1309/4885DGAT1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.